Printer Friendly

VERIDIEN ANNOUNCES OFFICIAL NOTICE OF PATENT ALLOWANCE FOR VIRAHOL 1

VERIDIEN ANNOUNCES OFFICIAL NOTICE OF PATENT ALLOWANCE FOR VIRAHOL 1
 TAMPA, Fla., June 5 /PRNewswire/ -- Veridien Corporation (OTC Bulletin Board: VERD), a healthcare products company headquartered in Tampa, Fla., announced today that official notice of patent allowance for Virahol 1 (the company's core technology) has been received from the United States Patent Office. The product is already registered as a high-level, hospital-grade disinfectant with the Environmental Protection Agency. "This gives us the only alcohol-based disinfectant in the world that is both patent protected and EPA registered," said Paul L. Simmons, chairman and chief executive officer of Veridien Corporation.
 The company has also successfully concluded its clinical trials of Veridien Cold Chemical Sterilant, based on the same technology as the hospital-grade disinfectant. In summary, these trials confirm the company's claim that Veridien's new sterilant, used in connection with Veridien's hospital-grade disinfectant and revolutionary Cold Chemical Sterilizing System, kills spores, bacteria, viruses and tuberculosis bacilli in less than 10 minutes at room temperature, "Additionally, the testing indicates that Veridien Cold Chemical Sterilant leaves no residue and is superior to all sterilants that are currently available," said Simmons.
 Veridien announced the completion of a private placement of $3.2 million of its common stock to overseas investors. Simmons said, "This financing provides a firm capital foundation to commence commercial distribution of its multiple product line." In addition, the company announced that the Pinellas County Industrial Council has cleared the road for the approval of the company's request for industrial revenue bonds for the acquisition and outfitting of manufacturing facilities, laboratories, and executive offices. Simmons said, "This substantially completes the funding program which the company initiated during 1991. We believe that this funding will allow us to maintain the leading edge of technology in infection control products and services for the healthcare industry."
 The company also announced that it has signed a national distribution agreement with the Dukal Corporation, giving Dukal nonexclusive rights to market the full line of the company's products to the healthcare, consumer and advertising specialty markets. Dukal, a national distributor of healthcare products, is headquartered in New York. Gerald LoDucca, Dukal's president, said, "Right now, the healthcare market in particular is looking for new systems and products to safely disinfect and sterilize medical and dental instruments and the medical environment. Veridien's products are not only unique, but the timing of their arrival is ideal and will provide for a whole new generation of disinfection and sterilization technology. Based on our research, Dukal believes the initial market for Veridien's products to be approximately $500 million, and believe that they can achieve significant market penetration into that market in a very short period of time. We are extremely pleased to be able to represent a company with such efficacious products, which are completely safe for the environment."
 In addition, Veridien announced that negotiations are currently under way with three additional major distributors for nonexclusive marketing rights.
 Finally, Simmons said, "The completion of the patent, capital raising, and marketing contract processes enable us to convert from a research and development company to full-scale operations."
 -0- 6/5/92
 /CONTACT: Paul L. Simmons or D. Jerry Diamond of Veridien Corporation, 813-623-1423/
 (VERD) CO: Veridien Corporation ST: Florida IN: MTC HEA SU:


JB-JJ -- FL001 -- 7342 06/05/92 09:03 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 5, 1992
Words:546
Previous Article:INDE TO ACQUIRE ICOM SERVICE BUREAU
Next Article:AUDITOR TIM MCCORMACK RELEASES SPECIAL GASOLINE REPORT
Topics:


Related Articles
VERIDIEN CORPORATION SEEKS INVESTMENT BANKING FIRM ASSISTANCE
/C O R R E C T I O N -- VERIDIEN/
VERIDIEN CORPORATION STARTS 30-DAY CLINICAL TRIALS FOR NEW CHEMICAL COLD STERILANT
VERIDIEN SHAREHOLDERS AMEND COMPANY'S BYLAWS TO PERMIT GREATER FLEXIBILITY IN APPOINTMENT OF DIRECTORS
CLARK JOINS VERIDIEN CORPORATION AS SENIOR CONSULTANT TO THE CHAIRMAN
VERIDIEN ACHIEVES PROFITABILITY AT CLOSE OF 1992
ISIS PHARMACEUTICALS RECEIVES FOUR PATENT ALLOWANCES FOR NOVEL ANTISENSE CHEMISTRY
CNS, INC., SAYS OFFICIAL NOTICE EXPECTED SOON ON PATENT FOR BREATHE RIGHT DEVICE
VERIDIEN PROJECTS FIRST QTR 2004 PROFIT.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters